Abstract
Background Modified Vaccinia Ankara (MVA), a vector-based vaccine that targets dendritic cells (DC) and induces cell-mediated immunity, is a promising HIV vaccine candidate. As MVA vaccination strategies continue to be explored, concerns arise regarding transferability to individuals with pre-existing immunity to vaccina, particularly military personnel. Prior reports suggest long-lasting vaccinia immunity after childhood vaccination. This study, conducted in a unique cohort of adult primary vaccinees, explores how pre-exisiting humoral immunity to vaccinia affects entry and transgene expression of MVA-vectored vaccines in a primary human DC infection model. Methods
Highlights
Modified Vaccinia Ankara (MVA), a vector-based vaccine that targets dendritic cells (DC) and induces cell-mediated immunity, is a promising HIV vaccine candidate
Sera were tested for inhibition of infection of DCs in vitro using either MVA-GFP or MVACMDR, an HIV vaccine candidate with env/gag/pol inserts, currently in clinical trials
Vaccinia binding antibody titers waned after 5 years and were undetectable 10 years after vaccination
Summary
Modified Vaccinia Ankara (MVA), a vector-based vaccine that targets dendritic cells (DC) and induces cell-mediated immunity, is a promising HIV vaccine candidate. As MVA vaccination strategies continue to be explored, concerns arise regarding transferability to individuals with pre-existing immunity to vaccina, military personnel. Prior reports suggest long-lasting vaccinia immunity after childhood vaccination. This study, conducted in a unique cohort of adult primary vaccinees, explores how pre-exisiting humoral immunity to vaccinia affects entry and transgene expression of MVA-vectored vaccines in a primary human DC infection model
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
